title: Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.
abstract: Gerbils show a neurokinin (NK)1 receptor pharmacological profile, which is similar to that observed in humans, and thus have become a commonly used species to test efficacy of NK1 receptor antagonists. The aim of this study was to determine whether systemic administration of the NK1 receptor antagonist GR-205171 produced anxiolytic-like effects in the elevated plus maze and in a novel contextual conditioned fear test using fear-potentiated startle (FPS). On the elevated plus maze, treatment with GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing produced anxiolytic-like effects in an increasing dose-response manner as measured by the percentage of open arm time and percentage of open arm entries. For contextual fear conditioning, gerbils were given 10 unsignaled footshocks (0.6 mA) at a 2-min variable interstimulus interval in a distinctive training context. Twenty-four hours after training, gerbils received treatment of GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing in which startle was elicited in the same context in which they were trained. Contextual FPS was defined as an increase in startle over pretraining baseline values. All drug dose levels (0.3, 1.0, and 5.0 mg/kg) significantly attenuated contextual FPS when compared with the vehicle control group. A control group, which received testing in a different context, showed little FPS. These findings support other evidence for anxiolytic activity of NK1 receptor antagonists and provide a novel conditioned fear test that may be an appropriate procedure to test other NK1 antagonists for preclinical anxiolytic activity in gerbils.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. sheldt@emory.edu
authors.forename: Scott A
authors.initials: SA
authors.lastname: Heldt
authors.forename: Michael
authors.initials: M
authors.lastname: Davis
authors.forename: Emiliangelo
authors.initials: E
authors.lastname: Ratti
authors.forename: Mauro
authors.initials: M
authors.lastname: Corsi
authors.forename: David
authors.initials: D
authors.lastname: Trist
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Ressler
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005239:Fear / Q000187:drug effects*; D005849:Gerbillinae; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D023421:Models, Animal; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D013216:Reflex, Startle / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D013777:Tetrazoles; C103207:vofopitant
references.citation: Neuroscience. 1995 Dec;69(4):1205-21
references.pmid: 8848108
references.citation: Pharmacol Biochem Behav. 1994 Sep;49(1):171-6
references.pmid: 7816869
references.citation: Psychophysiology. 2001 May;38(3):383-90
references.pmid: 11352126
references.citation: Peptides. 1990 Jan-Feb;11(1):163-7
references.pmid: 1692991
references.citation: Exp Brain Res. 1988;73(2):354-6
references.pmid: 2463935
references.citation: Psychopharmacology (Berl). 1987;92(2):180-5
references.pmid: 3110839
references.citation: Physiol Behav. 1996 Oct;60(4):1183-6
references.pmid: 8884951
references.citation: Pharmacol Biochem Behav. 1991 Aug;39(4):903-9
references.pmid: 1763110
references.citation: Behav Neurosci. 1995 Jun;109(3):379-87
references.pmid: 7662148
references.citation: Mol Imaging Biol. 2005 Jul-Aug;7(4):262-72
references.pmid: 16155744
references.citation: Brain Res. 2006 Mar 17;1078(1):151-8
references.pmid: 16494851
references.citation: Amino Acids. 2006 Oct;31(3):251-72
references.pmid: 16820980
references.citation: Behav Pharmacol. 2000 Sep;11(6):495-504
references.pmid: 11103915
references.citation: Biol Psychiatry. 2009 Jul 1;66(1):94-7
references.pmid: 19200949
references.citation: Neuropsychopharmacology. 2002 Sep;27(3):371-9
references.pmid: 12225694
references.citation: Eur J Pharmacol. 2001 Nov 30;432(1):43-51
references.pmid: 11734186
references.citation: Pharmacol Biochem Behav. 1994 Sep;49(1):133-41
references.pmid: 7816864
references.citation: Behav Neurosci. 1992 Apr;106(2):274-85
references.pmid: 1590953
references.citation: Pharmacol Rev. 1994 Dec;46(4):551-99
references.pmid: 7534932
references.citation: Brain Res Mol Brain Res. 1993 Apr;18(1-2):43-58
references.pmid: 7683074
references.citation: Eur J Pharmacol. 1994 Dec 27;271(2-3):481-7
references.pmid: 7705448
references.citation: Sci Am. 1994 Jun;270(6):50-7
references.pmid: 8023118
references.citation: Biol Psychiatry. 2007 Apr 15;61(8):1002-6
references.pmid: 16950220
references.citation: J Neurosci. 1995 Mar;15(3 Pt 2):2301-11
references.pmid: 7891168
references.citation: Eur J Pharmacol. 2001 Feb 2;412(3):255-64
references.pmid: 11166289
references.citation: Acta Physiol Scand. 1992 Nov;146(3):341-8
references.pmid: 1282765
references.citation: Am J Psychiatry. 2006 Apr;163(4):637-43
references.pmid: 16585438
references.citation: Biol Psychiatry. 2005 Jul 15;58(2):132-42
references.pmid: 16038684
references.citation: Pharmacol Biochem Behav. 1986 Mar;24(3):525-9
references.pmid: 2871560
references.citation: Behav Neurosci. 1992 Feb;106(1):72-80
references.pmid: 1554439
references.citation: Biophys J. 1992 Apr;62(1):59-60
references.pmid: 1376175
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4280-5
references.pmid: 15024126
references.citation: Biol Psychiatry. 2006 Oct 1;60(7):760-6
references.pmid: 16631127
references.citation: Behav Neurosci. 2000 Aug;114(4):749-59
references.pmid: 10959534
references.citation: Pharmacol Rev. 2002 Jun;54(2):285-322
references.pmid: 12037144
references.citation: Eur J Pharmacol. 1996 Sep 5;311(1):7-14
references.pmid: 8884230
references.citation: Science. 1992 May 1;256(5057):675-7
references.pmid: 1585183
references.citation: Curr Pharm Des. 2005;11(12):1529-47
references.pmid: 15892660
references.citation: J Neurosci Methods. 1985 Aug;14(3):149-67
references.pmid: 2864480
references.citation: Psychopharmacology (Berl). 2001 Oct;157(4):358-67
references.pmid: 11605094
references.citation: Neuropharmacology. 1991 Dec;30(12A):1263-7
references.pmid: 1787880
references.citation: Psychopharmacology (Berl). 1995 Apr;118(3):316-23
references.pmid: 7617825
references.citation: Behav Pharmacol. 2001 Nov;12(6-7):497-508
references.pmid: 11742144
references.citation: Neuropeptides. 1998 Feb;32(1):1-49
references.pmid: 9571643
references.citation: Br J Pharmacol. 2006 Feb;147(3):316-23
references.pmid: 16331282
references.citation: Science. 2008 Mar 14;319(5869):1536-9
references.pmid: 18276852
references.citation: Brain Res. 2001 Oct 12;915(2):170-5
references.pmid: 11595206
references.citation: Brain Res. 1999 Nov 27;848(1-2):90-5
references.pmid: 10612700
references.citation: Life Sci. 1998;63(25):2227-32
references.pmid: 9870708
references.citation: Br J Pharmacol. 2006 May;148(1):39-45
references.pmid: 16501582
references.citation: Eur J Neurosci. 2003 May;17(9):1736-46
references.pmid: 12752772
references.citation: Neuroreport. 1997 Mar 3;8(4):1031-4
references.pmid: 9141086
references.citation: Behav Brain Res. 2004 Oct 5;154(2):501-10
references.pmid: 15313039
references.citation: Curr Drug Targets. 2006 Aug;7(8):975-92
references.pmid: 16918326
references.citation: Behav Brain Res. 2002 Jul 18;133(2):363-8
references.pmid: 12110470
references.citation: J Pharmacol Exp Ther. 2002 May;301(2):536-42
references.pmid: 11961054
references.citation: Eur J Pharmacol. 1994 Sep 1;262(1-2):171-5
references.pmid: 7529183
references.citation: Brain Res. 1986 Sep 3;381(2):393-6
references.pmid: 2428438
references.citation: Psychopharmacology (Berl). 1979 Mar 29;62(1):1-7
references.pmid: 35808
references.citation: Neuropsychopharmacology. 2004 Feb;29(2):385-92
references.pmid: 14666114
references.citation: Neuropsychopharmacology. 2002 Sep;27(3):357-70
references.pmid: 12225693
references.citation: Pharmacol Biochem Behav. 1996 May;54(1):21-30
references.pmid: 8728535
references.citation: Behav Brain Res. 1994 Jul 29;63(1):81-8
references.pmid: 7524534
references.citation: Life Sci. 2004 Feb 6;74(12):1445-63
references.pmid: 14729395
references.citation: Eur J Pharmacol. 1999 Jun 30;375(1-3):51-60
references.pmid: 10443564
references.citation: Psychopharmacology (Berl). 1989;99(1):48-53
references.pmid: 2528779
references.citation: J Neurosci. 1997 Dec 1;17(23):9353-60
references.pmid: 9364080
references.citation: Psychopharmacology (Berl). 1992;106(1):102-10
references.pmid: 1738787
references.citation: Neuropsychobiology. 1988;20(2):82-6
references.pmid: 3151011
references.citation: Neuropsychopharmacology. 2003 Apr;28(4):654-63
references.pmid: 12655310
references.citation: Behav Brain Res. 2000 Jun 1;110(1-2):83-95
references.pmid: 10802306
references.citation: J Comp Neurol. 2005 Oct 3;490(4):335-53
references.pmid: 16127708
references.citation: Science. 1998 Sep 11;281(5383):1640-5
references.pmid: 9733503
references.citation: J Comp Neurol. 2002 May 20;447(1):82-97
references.pmid: 11967897
references.citation: Biol Psychiatry. 2007 Feb 1;61(3):389-95
references.pmid: 16730332
references.citation: Behav Brain Res. 1986 Aug;21(2):119-27
references.pmid: 2428383
references.citation: Neuropharmacology. 2003 Aug;45(2):231-41
references.pmid: 12842129
references.citation: Eur J Pharmacol. 1991 May 17;197(2-3):237-8
references.pmid: 1717291
references.citation: Neuropharmacology. 2003 Mar;44(4):516-23
references.pmid: 12646288
references.citation: Br J Pharmacol. 1991 Oct;104(2):292-3
references.pmid: 1665729
references.citation: Neuropeptides. 1994 Apr;26(4):253-60
references.pmid: 7518054
references.citation: J Comp Neurol. 1998 Sep 7;398(4):473-90
references.pmid: 9717704
references.citation: Neurosci Biobehav Rev. 1997 Nov;21(6):801-10
references.pmid: 9415905
references.citation: Neuroendocrinology. 1987 Jun;46(1):75-81
references.pmid: 2441310
references.citation: Pharmacol Biochem Behav. 1995 Oct;52(2):297-303
references.pmid: 8577794
references.citation: Eur J Pharmacol. 2005 Jan 10;507(1-3):99-105
references.pmid: 15659299
references.citation: Psychophysiology. 1997 Jul;34(4):451-8
references.pmid: 9260498
references.citation: Braz J Med Biol Res. 1997 Mar;30(3):289-304
references.pmid: 9246227
references.citation: Ann N Y Acad Sci. 1985;448:255-74
references.pmid: 2411182
references.citation: Int J Psychophysiol. 1999 Apr;32(1):63-73
references.pmid: 10192009
references.citation: J Abnorm Psychol. 1996 Feb;105(1):89-96
references.pmid: 8666715
references.citation: Behav Brain Res. 2007 Sep 4;182(2):301-7
references.pmid: 17208313
references.citation: Regul Pept. 1996 Aug 27;65(1):45-53
references.pmid: 8876035
references.citation: Behav Pharmacol. 1994 Jun;5(3):369-373
references.pmid: 11224289
references.citation: Pharmacol Biochem Behav. 1997 Nov;58(3):747-52
references.pmid: 9329068